VivArt-X has successfully raised funding from Borski Fund and other investors to enhance its regenerative solutions for breast cancer patients, positioning itself in a growing FemTech market that addresses significant healthcare disparities.

Information on the Target

VivArt-X, founded by Dan Jing Wu and Patricia Dankers, provides personalized regenerative solutions aimed at assisting breast cancer patients during their recovery process. This innovative start-up, based in Brabant, recently concluded an extension financing round with Borski Fund, alongside earlier investors such as Brabant Startup Fund, TUe Participations, BOM (Brabant Development Agency), and a network of informal investors.

In the Netherlands, a woman faces a 1 in 7 chance of developing breast cancer. A significant number of these patients require breast reconstruction surgeries, which can often lead to complications that further deteriorate their health. VivArt-X has developed a groundbreaking synthetic, biodegradable biomaterial that facilitates improved regeneration and grafting of the necessary cells for these transplant procedures, ultimately enhancing the quality of life for breast cancer patients.

Industry Overview in the Netherlands

The landscape of women's health in the Netherlands presents a pressing concern, particularly with the increasing incidence of breast cancer. Despite advancements in medical technology and treatment protocols, disparities re